Cargando…
Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
Classical Hodgkin’s lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436782/ https://www.ncbi.nlm.nih.gov/pubmed/28546779 http://dx.doi.org/10.2147/JBM.S117452 |